Search / Trial NCT00002296

The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease

Launched by NEWPORT PHARMACEUTICALS INTERNATIONAL · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

T Lymphocytes Immune Tolerance Inosine Pranobex Killer Cells T Lymphocytes, Helper Inducer Acquired Immunodeficiency Syndrome Aids Related Complex

ClinConnect Summary

No description provided

Gender

MALE

Eligibility criteria

  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following are excluded:
  • History of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction and severe gastric ulcer.
  • Lymphoid malignancy.
  • Infectious mononucleosis caused by cytomegalovirus or Epstein-Barr virus.
  • Heart disease (especially if receiving cardiac glycosides).
  • Hemophilia.
  • Patients with the following are excluded:
  • * Kaposi's sarcoma or overt opportunistic infections as follows:
  • Candida albicans, Pneumocystis carinii, Herpes simplex, Cryptococcus neoformans, Histoplasma capsulatum, Mycobacterium avium-intracellulare, Toxoplasma gondii, Legionella, Cryptosporidium, Isospora, and Papovavirus.
  • Active evidence of infectious mononucleosis caused by Epstein-Barr virus (EBV) or cytomegalovirus (CMV) as determined by heterophil test (EBV) or cell culture (CMV).
  • History of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction, and severe gastric ulcer.
  • Critical illness.
  • Condition requiring hospitalization.
  • Women of childbearing age are excluded.
  • Hemophilia.
  • Prior Medication:
  • Excluded:
  • Steroids.
  • Cytotoxic immunosuppressive agents.
  • Antiviral medicine.
  • Prior Treatment:
  • Excluded:
  • Radiotherapy.
  • Patients who have unexplained immunodepression and are at risk of developing AIDS.
  • Patients with prolonged generalized lymphadenopathy for 3 or more months (greater than 1 cm at two or more noncontiguous sites).
  • IV drug abuse.

About Newport Pharmaceuticals International

Newport Pharmaceuticals International is a leading biopharmaceutical company dedicated to advancing innovative therapies that address unmet medical needs across various therapeutic areas. With a strong focus on research and development, Newport Pharmaceuticals harnesses cutting-edge science and technology to create effective treatments aimed at improving patient outcomes. The company is committed to conducting rigorous clinical trials that adhere to the highest ethical standards, ensuring safety and efficacy while fostering collaboration with healthcare professionals and regulatory bodies. Through its dedication to innovation and excellence, Newport Pharmaceuticals International strives to make a meaningful impact on global health.

Locations

Laguna Hills, California, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials